PREFERRED DRUG LIST MEETING SCHEDULE

State of Montana
Department of Public Health & Human Services

Montana Medicaid Drug Use Review Board / Formulary Committee Meeting

The Montana Medicaid Drug Utilization Review Board/Formulary Committee will hold a meeting on :

Date: September 22, 2004
Time: 1:00 pm – 4:00 pm Mountain Time
Location: Montana Association of Counties Building (MACO)
2715 Skyway Drive, Helena

At this time the Montana Medicaid Drug Utilization Review Board / Formulary Committee will review the following drug classes for Preferred Drug List (PDL) review:

Drug Class Reviews

- PROTON PUMP INHIBITORS (Oral)
- BISPHOSPHONATES (Oral)
- ANGIOTENSIN RECEPTOR BLOCKERS
- ANGIOTENSIN RECEPTOR BLOCKERS & DIURETICS
- THIAZOLIDINEDIONES-ORAL ANTIDIABETIC
- INSULINS
- MEGLITINIDES- ORAL ANTIDIABETICS
- ALPHA-GLUCOSIDASE INHIBITORS-ORAL ANTIDIABETIC
- 2ND GENERATION SULFONYLUREAS
- NASAL CALCITONINS

Public Testimony will be taken into consideration in the committee's recommendations as to which drugs should be given preferred status in the above listed classes of medications for the state's Medicaid program. Sign-up for public comment will occur between 12:30pm -12:55 pm outside the Conference Room. See the General Procedures for Public Comment section of this document for further details.

Clinical Information: Clinical information (preferably in electronic format in the AMCP style dossier) may be sent on the following drug classes by September 15, 2004 to:

Mark Eichler, Mountain-Pacific Quality Health Foundation,
Tel: (406) 457-5818, meichler@mpqhf.org .

Note: This request constitutes a request for information pertaining to peer-reviewed literature including off label peer-reviewed studies or AMCP style - dossiers. Please note that all information sent is subject to public disclosure and that proprietary and confidential material should not be sent and that the sender accepts responsibility for all information sent.

Montana Medicaid

Department of Public Health and Human Services

DUR Board Meeting

General Procedures for Public Comment

1. Thirty minutes prior to the beginning of the DUR Board Meeting, a sign up sheet for Public Comment will be posted for Pharmaceutical Manufacturers and Special Interest Groups for each Drug Class to be reviewed.
2. Sign up will close 5 minutes prior to the beginning of the DUR Board Meeting.
3. Speakers will be assigned on a first come basis respective to each Drug Class discussion.
4. Speakers will be asked to present on their corresponding product or interest.
   a. Public comment will be allowed for twenty (20) minutes before each class review and speakers will have three (3) to five (5) minutes per speaker depending on the number of speakers for each drug class group.
   b. Speakers must state their name, their affiliation, and whom they are speaking on behalf of or on request of, with any funding or payment agreements disclosed. Any studies cited during the presentation should be referenced with the primary source of funding included.
   c. Handouts are limited to two (2) pages (paper size: 8.5" by 11", one side only) of documentation. Access to computers or other technology presentation devices for slide presentations will not be available during this comment period.
   d. Public Comment will be limited to clinical and social comments; pricing or financial information regarding products and outcomes will not be permissible. The Board will be utilizing clinical information only. Information regarding pricing, cost or any other information of a financial nature will not be permissible and should not be discussed in handouts or during presentation by any public speaker.
   e. The speakers presenting hand-outs are asked to provide at least fifteen (15) copies that will be distributed by Foundation staff to the DUR Board members and the State members present.
   f. Copies will be collected by Foundation staff members at the time of sign-up.
   g. The State, FHSC and the DUR Board will be allowed to ask questions if needed during the presentation or after for clarification or discussion. Presenters will only be allowed to answer questions when specifically requested to do so by the Board during the remainder of the meeting.
   h. It is not permissible for presenters to interject or ask questions to DUR Board members during the session
5. Individual products may only be represented by one presentation. For example, a product jointly ventured by two pharmaceutical companies can only be represented once.